Awareness, Care & Treatment In Obesity Management - An Observation in Asia Pacific
ACTION-APAC
2 other identifiers
observational
12,404
9 countries
9
Brief Summary
ACTION APAC is a cross-sectional, observational, descriptive, and exploratory survey-based study without collection of laboratory data. The study is not related to any specific treatment options or pharmaceutical product. Collection of data will be performed via quantitative online survey by a third-party vendor through existing databases/panels in APAC region. The goal of this study is to provide insights to drive awareness around the needs of People Living with Obesity (PLwO) and Health Care Professionals (HCPs) involved in obesity treatment and management.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2022
Shorter than P25 for all trials
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 11, 2022
CompletedFirst Posted
Study publicly available on registry
February 22, 2022
CompletedStudy Start
First participant enrolled
April 26, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 23, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
May 23, 2022
CompletedJune 14, 2022
June 1, 2022
27 days
February 11, 2022
June 13, 2022
Conditions
Outcome Measures
Primary Outcomes (7)
Weight loss motivators for improving health of PLwO
Multi-select from defined list
At the time of survey response (Day 1)
Weight loss barriers for improving health of PLwO
Multi-select from defined list
At the time of survey response (Day 1)
Weight loss management for improving health of PLwO
Multi-select from defined list
At the time of survey response (Day 1)
Weight loss responsibility for improving health of PLwO
Multi-select from defined list
At the time of survey response (Day 1)
Proportion of PLwO who made serious weight loss effort
Number of weight loss efforts; percentage of patients
At the time of survey response (Day 1)
Response to weight loss discussions
Single select from defined list
At the time of survey response (Day 1)
Attitudes towards obesity and weight management and Interactions of PLwOs with HCPs
5-point Likert scales
At the time of survey response (Day 1)
Study Arms (2)
People / Person Living with Obesity (PLwO)
From online, general population consumer panels
Health Care Professionals (HCPs)
HCPs treating people who have obesity
Interventions
No treatment given
Eligibility Criteria
The respondent population will include people living with obesity (PLwO) and health care professionals (HCPs) involved in obesity treatment and management.
You may qualify if:
- People Living with Obesity
- Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Male or female, aged above or equal to 18 years at the time of signing informed consent
- Lives in one of the target countries
- Current BMI of at least 25 kg/m\^2 for all countries (except Singapore which has current BMI 27 kg/m\^2) based on self-reported height and weight
- Health Care Professionals
- Informed consent before any study related activities (study-related activities are any procedure related to recording/collection of data according to protocol)
- Male or female, aged greater than or equal to 18 years at the time of signing informed consent.
- Physician
- Primary Care Providers (PCPs) whose specialty is Family practice, General practice, Internal Medicine
- Non-PCP Specialties whose specialty is Endocrinologist, Cardiologist, Gastroenterologist, Obstetrics/Gynaecologist, Bariatrics/Obesity Medicine, Nutrition Specialist (physician) Orthopaedist, Aesthetics Medicine
- Specialty is not surgeon (including bariatric or plastic surgeon)
- Practices in the target countries
- In clinical practice for at least 2 years
- Spends at least 50% time in direct patient care
- +2 more criteria
You may not qualify if:
- People Living with obesity
- Previous participation in this study. Participation is defined as having given online consent in this study
- Currently pregnant
- Participates in intense fitness or body building programs
- Has had significant, unintentional weight loss (due to major injury, illness, etc) in the past 6 months
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- Health Care Providers
- Previous participation in this study. Participation is defined as having given informed consent in this study.
- Unwillingness, inability, or language barriers precluding adequate understanding or cooperation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Novo Nordisk A/Slead
Study Sites (9)
Novo Nordisk Investigational Site
Dhaka, Bangladesh
Novo Nordisk Investigational Site
Bangalore, India
Novo Nordisk Investigational Site
Jakarta, Indonesia
Novo Nordisk Investigational Site
Kuala Lumpur, Malaysia
Novo Nordisk Investigational Site
Karachi, Pakistan
Novo Nordisk Investigational Site
Manila, Philippines
Novo Nordisk Investigational Site
Singapore, Singapore
Novo Nordisk Investigational Site
Bangkok, Thailand
Novo Nordisk Investigational Site
Ho Chi Minh City, Vietnam
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Clinical Transparency (dept. 2834)
Novo Nordisk A/S
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 11, 2022
First Posted
February 22, 2022
Study Start
April 26, 2022
Primary Completion
May 23, 2022
Study Completion
May 23, 2022
Last Updated
June 14, 2022
Record last verified: 2022-06
Data Sharing
- IPD Sharing
- Will share
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com